The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth ...

A Nova radio host has admitted live on-air to taking a weight loss drug popular with celebrities that costs an arm and a leg ...

Regulators will tighten eligibility criteria for weight loss jabs such as Wegovy and Ozempic in a crackdown on inappropriate ...

Ozempic, which accounts for 41% of the company's sales, is an injectable anti-diabetic treatment that became wildly popular ...

Michael 'Wippa' Wipfli made a bombshell admission live on-air on Wednesday that he was taking an expensive celebrity weight ...

Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...